Tevogen Bio Broadens Relationship with Microsoft to Deepen AI Collaboration

 

• This expansion is in addition to the previously announced Microsoft for Startups program.
• PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target identification.
• Tevogen Bio is also proactively investigating potential treatments for Human Papillomavirus (HPV).

Tevogen.AI, Tevogen Bio’s artificial intelligence effort, will integrate Microsoft’s advanced AI tools and the Microsoft Azure cloud platform into two key objectives:

1. Rapidly Expanding the ExacTcell™ Technology Pre-Clinical Pipeline
   Building on the successful trial results of TVGN 489, Tevogen Bio aims to utilize machine learning to perform critical simulations that will accelerate the identification of new targets. By leveraging Microsoft’s AI, the company can analyze large datasets across the genome with greater speed and accuracy.
   
2. Developing Proprietary Algorithms to Decode HLA-T Cell Interactions
   Tevogen.AI, in collaboration with Microsoft domain experts, will create new algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells. This capability is expected to significantly enhance Tevogen Bio’s understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data.

https://www.globenewswire.com/news-release/2025/01/24/3015137/0/en/Tevogen-Bio-Broadens-Relationship-with-Microsoft-to-Deepen-Artificial-Intelligence-Collaboration-and-Develop-PredicTcell-Technology-on-Azure.html